solid tumors
Showing 1 - 25 of >10,000
Refractory Solid Tumors, Relapsed Solid Tumors Trial in Beijing (KSX01-TCRT cell therapy)
Recruiting
- Refractory Solid Tumors
- Relapsed Solid Tumors
- KSX01-TCRT cell therapy
-
Beijing, ChinaCancer Institute and Hospital, Chinese Academy of Medical Scienc
Nov 21, 2023
NHWD-870 in Advanced Solid Tumors or Lymphomas Carrying NUT
Recruiting
- Advanced Solid Tumors or Lymphomas
-
Changsha, Hunan, ChinaHunan Provincal Tumor Hospital
Oct 5, 2023
Advanced Solid Tumors With Neuroendocrine Differentiation Trial (surufatinib?serplulimab)
Not yet recruiting
- Advanced Solid Tumors With Neuroendocrine Differentiation
- (no location specified)
Nov 27, 2023
Solid Tumors Trial (IBR854 Cell Injection)
Not yet recruiting
- Solid Tumors
- IBR854 Cell Injection
- (no location specified)
Aug 14, 2023
Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors Trial (RO7566802, Atezolizumab)
Not yet recruiting
- Locally Advanced Solid Tumors
- +2 more
- (no location specified)
Sep 4, 2023
Metastatic Solid Tumors, Advanced Solid Tumors Trial (MK-0472, Pembrolizumab)
Not yet recruiting
- Metastatic Solid Tumors
- Advanced Solid Tumors
- MK-0472
- Pembrolizumab
- (no location specified)
May 2, 2023
GT316,Solid Tumors,Adult Trial in Zhengzhou (GT316)
Recruiting
- GT316,Solid Tumors,Adult
- GT316
-
Zhengzhou, Henan, ChinaThe First Affiliated Hospital of Zhengzhou University
Oct 16, 2023
Advanced Solid Tumors Trial (SKB410 for injection)
Not yet recruiting
- Advanced Solid Tumors
- SKB410 for injection
- (no location specified)
Jun 13, 2023
Advanced Malignant Solid Tumors Trial (Neoantigen mRNA Personalised Cancer vaccine)
Not yet recruiting
- Advanced Malignant Solid Tumors
- Neoantigen mRNA Personalised Cancer vaccine
- (no location specified)
Jul 16, 2023
Advanced Solid Tumors, B-cell Non-Hodgkin Lymphomas Trial (ATG-031)
Not yet recruiting
- Advanced Solid Tumors
- B-cell Non-Hodgkin Lymphomas
- (no location specified)
Aug 31, 2023
HER2-expressing Advanced Solid Tumors Trial (SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor
Not yet recruiting
- HER2-expressing Advanced Solid Tumors
- SHR-A1811 combined with Pyrotinib.
- SHR-A1811 combined with other antitumor therapies
- (no location specified)
Aug 28, 2023
Precision Medicine Treatment for Refractory Solid Tumors
Recruiting
- Refractory Solid Tumors
- Next Generation Sequencing
-
Tianjin, Tianjin, ChinaTianjin Medical University Second Hospital
Sep 2, 2023
Advanced Solid Tumors Trial in Hangzhou (ZGGS15)
Not yet recruiting
- Advanced Solid Tumors
- ZGGS15
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
May 17, 2023
Tumor Vaccines for Solid Tumors
Recruiting
- Glioma
- Solid Tumor
- tumor vaccine
- +3 more
-
Shanghai, Shanghai, ChinaHuashan Hospital, Fudan University
Oct 22, 2023
Refractory Solid Tumors Trial in Houston (Eribulin, Irinotecan, Temozolomide)
Recruiting
- Refractory Solid Tumors
- Eribulin
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 22, 2023
Solid Tumors, Adult Trial in Xuzhou (TIL injection)
Recruiting
- Solid Tumors, Adult
- TIL injection
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital Of Xuzhou Medical University
Oct 12, 2023
NSCLC, Breast Cancer, HNSCC Trial in Chang chun (YL202 should be intravenously infused)
Not yet recruiting
- NSCLC
- +3 more
- YL202 should be intravenously infused
-
Chang chun, Jilin, ChinaJilin Provincial Cancer Hospital
Oct 25, 2023
Mesothelin-positive Advanced Malignant Solid Tumors Trial (Anti-mesothelin CAR-T cells)
Not yet recruiting
- Mesothelin-positive Advanced Malignant Solid Tumors
- Anti-mesothelin CAR-T cells
- (no location specified)
Mar 13, 2023